References
- Gambacciani M, Torelli MG, Martella L, et al. Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. Climacteric 2015;18(Suppl 1):43–8
- Gambacciani M, Albertin E, Torelli MG, et al. Sexual function after vaginal erbium laser: the results of a large multicentric, prospective study. Climacteric 2020;23(Suppl 1):S24–S27
- Erel CT, Fistonić I, Gambacciani M, Oner Y, Fistonić N. Er:YAG laser in hysterectomized women with stress urinary incontinence: A VELA retrospective cohort non-inferiority study. Climacteric 2020;23(Suppl 1):S18–S23
- Gambacciani M, Cervigni M, Gaspar A, et al. Safety of vaginal erbium laser: a review of 113,000 patients treated in the past 8 years. Climacteric 2020;23(Suppl 1):S28–S32
- Tadir Y, Gaspar A, Lev-Sagie A, et al. Light and energy-based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med 2017;49:137–59
- FDA Warns Against Use of Energy-Based Devices to Perform Vaginal ‘Rejuvenation’ or Vaginal Cosmetic Procedures: FDA Safety Communication. July 30, 2018
- Ahluwalia J, Avram MM, Ortiz AE. Lasers and energy-based devices marketed for vaginal rejuvenation: a cross-sectional analysis of the MAUDE Database. Lasers Surg Med 2019;51:671–7
- Gordon C, Gonzales S, Krychman ML. Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. Menopause 2019;26:423–7
- The American College of Obstetricians and Gynecologists and the American Congress of Obstetricians and Gynecologists: Fractional Laser Treatment of Vulvovaginal Atrophy and U.S. Food and Drug Administration Clearance: Position Statement. Available at www.acog.org/-/media/434ADADB30E846B09D359F3F1432510E.pdf
- Gambacciani M, Palacios S. Laser therapy for the restoration of vaginal function. Maturitas 2017;99:10–15
- Blaganje M, Šćepanović D, Žgur L, Verdenik I, Pajk F, Lukanović A. Non-ablative Er:YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2018;224:153–8
- Gambacciani M, Levancini M, Russo E, Vacca L, Simoncini T, Cervigni M. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric 2018;21:148–52
- Fistonic I, Fistonic N. Baseline ICIQ‐UI score, body mass index, age, average birth weight, and perineometry duration as promising predictors of the short‐term efficacy of Er:YAG laser treatment in stress urinary incontinent women: a prospective cohort study. Lasers Surg Med 2018;50:636–43
- Okui N. Comparison between erbium-doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence. World J Urol 2019;37:885–9
- Erel CT, Inan D, Mut A. Predictive factors for the efficacy of Er:YAG laser treatment of urinary incontinence. Maturitas 2020;132:1–6
- Lin KL, Chou SH, Long CY. Effect of Er:YAG laser for women with stress urinary incontinence. BioMed Research International Volume 2019, Article ID 7915813, https://doi.org/10.1155/2019/7915813
- Okui N. Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists. World J Urol 2019;37:2459–66
- Erel CT, Carazo Fernandes LD, Inan D, Makul M. Er:YAG laser treatment of urinary incontinence after failed TOT/TVT procedures. Eur J Obstet Gynecol Reprod Biol 2020;252:399–403